Unknown

Dataset Information

0

Non-Covalent Inhibitors of SARS-CoV-2 Papain-Like Protease (PLpro): In Vitro and In Vivo Antiviral Activity.

ABSTRACT: The SARS-CoV-2 papain-like protease (PLpro), essential for viral processing and immune response disruption, is a promising target for treating acute infection of SARS-CoV-2. To date, there have been no reports of PLpro inhibitors with both submicromolar potency and animal model efficacy. To address the challenge of PLpro's featureless active site, a noncovalent inhibitor library with over 50 new analogs was developed, targeting the PLpro active site by modulating the BL2-loop and engaging the BL2-groove. Notably, compounds 42 and 10 exhibited strong antiviral effects and were further analyzed pharmacokinetically. 10, in particular, showed a significant lung accumulation, up to 12.9-fold greater than plasma exposure, and was effective in a mouse model of SARS-CoV-2 infection, as well as against several SARS-CoV-2 variants. These findings highlight the potential of 10 as an in vivo chemical probe for studying PLpro inhibition in SARS-CoV-2 infection.

SUBMITTER: Velma GR 

PROVIDER: S-EPMC11345844 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

The SARS-CoV-2 papain-like protease (PLpro), essential for viral processing and immune response disruption, is a promising target for treating acute infection of SARS-CoV-2. To date, there have been no reports of PLpro inhibitors with both submicromolar potency and animal model efficacy. To address the challenge of PLpro's featureless active site, a noncovalent inhibitor library with over 50 new analogs was developed, targeting the PLpro active site by modulating the BL2-loop and engaging the BL  ...[more]

Similar Datasets

Unknown Mercapto-pyrimidines are reversible covalent inhibitors of the papain-like protease (PLpro) and inhibit SARS-CoV-2 (SCoV-2) replication.
| S-EPMC10259201 | biostudies-literature
Unknown Identification of SARS-CoV-2 Papain-like Protease (PLpro) Inhibitors Using Combined Computational Approach.
| S-EPMC8805381 | biostudies-literature
Unknown SARS-COV-2 Coronavirus Papain-like Protease PLpro as an Antiviral Target for Inhibitors of Active Site and Protein-Protein Interactions.
| S-EPMC9984130 | biostudies-literature
Unknown Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2
| S-SCDT-EMBOJ-2020-106275 | biostudies-other
Unknown SARS-CoV-2 papain-like protease (PLpro) inhibitory and antiviral activity of small molecule derivatives for drug leads.
| S-EPMC10842477 | biostudies-literature
Unknown Binding of SARS-CoV Covalent Non-Covalent Inhibitors to the SARS-CoV-2 Papain-Like Protease and Ovarian Tumor Domain Deubiquitinases.
| S-EPMC8227062 | biostudies-literature
Unknown Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2.
| S-EPMC7461020 | biostudies-literature
Unknown Repurposing Known Drugs as Covalent and Non-covalent Inhibitors of the SARS-CoV-2 Papain-Like Protease.
| S-EPMC7701290 | biostudies-literature
Unknown Exploring naphthyl derivatives as SARS-CoV papain-like protease (PLpro) inhibitors and its implications in COVID-19 drug discovery.
| S-EPMC7936608 | biostudies-literature
Unknown Design of quinoline SARS-CoV-2 papain-like protease inhibitors as oral antiviral drug candidates.
| S-EPMC11825904 | biostudies-literature